Urokinase (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Urokinase" in English language version.

refsWebsite

Global rank English rank

20nih.gov

4^th place

15doi.org

2^nd place

3semanticscholar.org

11^th place

8^th place

2ensembl.org

1,626^th place

1,007^th place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1fccc.edu

low place

1legacy.com

672^nd place

400^th place

1harvard.edu

18^th place

17^th place

clinicaltrials.gov

"Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery". ClinicalTrials.gov. 28 March 2012.

doi.org

Degryse B (1 June 2011). "The urokinase receptor system as strategic therapeutic target: challenges for the 21st century". Current Pharmaceutical Design. 17 (19): 1872–1873. doi:10.2174/138161211796718161. PMID 21711231.
Tang L, Han X (March 2013). "The urokinase plasminogen activator system in breast cancer invasion and metastasis". Biomedicine & Pharmacotherapy. 67 (2): 179–182. doi:10.1016/j.biopha.2012.10.003. PMID 23201006.
Nagai M, Hiramatsu R, Kanéda T, Hayasuke N, Arimura H, Nishida M, Suyama T (Dec 1985). "Molecular cloning of cDNA coding for human preprourokinase". Gene. 36 (1–2): 183–188. doi:10.1016/0378-1119(85)90084-8. PMID 2415429.
Vincenza Carriero M, Franco P, Vocca I, Alfano D, Longanesi-Cattani I, Bifulco K, et al. (January 2009). "Structure, function and antagonists of urokinase-type plasminogen activator". Frontiers in Bioscience. 14 (10): 3782–3794. doi:10.2741/3488. PMID 19273310.
Bager R, Kristensen TK, Jensen JK, Szczur A, Christensen A, Andersen LM, et al. (August 2012). "Urokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains". The Journal of Biological Chemistry. 287 (33): 27526–27536. doi:10.1074/jbc.M112.369207. PMC 3431643. PMID 22733817.
Geiger M, Huber K, Wojta J, Stingl L, Espana F, Griffin JH, Binder BR (August 1989). "Complex formation between urokinase and plasma protein C inhibitor in vitro and in vivo". Blood. 74 (2): 722–728. doi:10.1182/blood.V74.2.722.722. PMID 2752144.
España F, Berrettini M, Griffin JH (August 1989). "Purification and characterization of plasma protein C inhibitor". Thrombosis Research. 55 (3): 369–384. doi:10.1016/0049-3848(89)90069-8. PMID 2551064.
Madunić J (December 2018). "The Urokinase Plasminogen Activator System in Human Cancers: An Overview of Its Prognostic and Predictive Role". Thrombosis and Haemostasis. 118 (12): 2020–2036. doi:10.1055/s-0038-1675399. PMID 30419600.
Mahmood N, Mihalcioiu C, Rabbani SA (2018). "Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications". Frontiers in Oncology. 8: 24. doi:10.3389/fonc.2018.00024. PMC 5816037. PMID 29484286.
Matthews H, Ranson M, Kelso MJ (November 2011). "Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?". International Journal of Cancer. 129 (9): 2051–2061. doi:10.1002/ijc.26156. PMID 21544803. S2CID 205943879.
Ouriel K, Gray B, Clair DG, Olin J (March 2000). "Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis". Journal of Vascular and Interventional Radiology. 11 (3): 295–298. doi:10.1016/S1051-0443(07)61420-1. PMID 10735422.
Cinà CS, Goh RH, Chan J, Kenny B, Evans G, Rawlinson J, Gill G (November 1999). "Intraarterial catheter-directed thrombolysis: urokinase versus tissue plasminogen activator". Annals of Vascular Surgery. 13 (6): 571–575. doi:10.1007/s100169900300. PMID 10541608. S2CID 470599.
Macfarlane RG, Pilling J (June 1947). "Fibrinolytic activity of normal urine". Nature. 159 (4049): 779. Bibcode:1947Natur.159Q.779M. doi:10.1038/159779a0. PMID 20241608. S2CID 4125748.
"Abstracts of Papers Read". American Journal of Physiology. Legacy Content. 171 (3): 704–781. 30 November 1952. doi:10.1152/ajplegacy.1952.171.3.704. Normal human and dog urine contains fibrinolysin (plasmin) and a potent activator of profibrinolysin (plasminogen). The activator, which we have designated urokinase, can be concentrated and partially purified by acetone or alcohol fractionation methods.
Celander DR, Guest MM (August 1960). "The biochemistry and physiology of urokinase". The American Journal of Cardiology. 6 (2): 409–419. doi:10.1016/0002-9149(60)90333-7. PMID 13808740.

ensembl.org

May2017.archive.ensembl.org

GRCh38: Ensembl release 89: ENSG00000122861 – Ensembl, May 2017
GRCm38: Ensembl release 89: ENSMUSG00000021822 – Ensembl, May 2017

fccc.edu

"Fox Chase Cancer Center : New Small Molecule Inhibitor Could be a Safe and First-Line Treatment for Metastatic Breast Cancer". Press Release. Temple University Health System.

harvard.edu

ui.adsabs.harvard.edu

Macfarlane RG, Pilling J (June 1947). "Fibrinolytic activity of normal urine". Nature. 159 (4049): 779. Bibcode:1947Natur.159Q.779M. doi:10.1038/159779a0. PMID 20241608. S2CID 4125748.

legacy.com

"Evelyn Nicol 1930 - 2020 - Obituary". www.legacy.com. Retrieved 2020-08-28.

nih.gov

pubmed.ncbi.nlm.nih.gov

Degryse B (1 June 2011). "The urokinase receptor system as strategic therapeutic target: challenges for the 21st century". Current Pharmaceutical Design. 17 (19): 1872–1873. doi:10.2174/138161211796718161. PMID 21711231.
Tang L, Han X (March 2013). "The urokinase plasminogen activator system in breast cancer invasion and metastasis". Biomedicine & Pharmacotherapy. 67 (2): 179–182. doi:10.1016/j.biopha.2012.10.003. PMID 23201006.
Nagai M, Hiramatsu R, Kanéda T, Hayasuke N, Arimura H, Nishida M, Suyama T (Dec 1985). "Molecular cloning of cDNA coding for human preprourokinase". Gene. 36 (1–2): 183–188. doi:10.1016/0378-1119(85)90084-8. PMID 2415429.
Vincenza Carriero M, Franco P, Vocca I, Alfano D, Longanesi-Cattani I, Bifulco K, et al. (January 2009). "Structure, function and antagonists of urokinase-type plasminogen activator". Frontiers in Bioscience. 14 (10): 3782–3794. doi:10.2741/3488. PMID 19273310.
Bager R, Kristensen TK, Jensen JK, Szczur A, Christensen A, Andersen LM, et al. (August 2012). "Urokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains". The Journal of Biological Chemistry. 287 (33): 27526–27536. doi:10.1074/jbc.M112.369207. PMC 3431643. PMID 22733817.
Geiger M, Huber K, Wojta J, Stingl L, Espana F, Griffin JH, Binder BR (August 1989). "Complex formation between urokinase and plasma protein C inhibitor in vitro and in vivo". Blood. 74 (2): 722–728. doi:10.1182/blood.V74.2.722.722. PMID 2752144.
España F, Berrettini M, Griffin JH (August 1989). "Purification and characterization of plasma protein C inhibitor". Thrombosis Research. 55 (3): 369–384. doi:10.1016/0049-3848(89)90069-8. PMID 2551064.
Madunić J (December 2018). "The Urokinase Plasminogen Activator System in Human Cancers: An Overview of Its Prognostic and Predictive Role". Thrombosis and Haemostasis. 118 (12): 2020–2036. doi:10.1055/s-0038-1675399. PMID 30419600.
Mahmood N, Mihalcioiu C, Rabbani SA (2018). "Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications". Frontiers in Oncology. 8: 24. doi:10.3389/fonc.2018.00024. PMC 5816037. PMID 29484286.
Jankun J, Skrzypczak-Jankun E (July 1999). "Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride". Cancer Biochemistry Biophysics. 17 (1–2): 109–123. PMID 10738907.
Matthews H, Ranson M, Kelso MJ (November 2011). "Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?". International Journal of Cancer. 129 (9): 2051–2061. doi:10.1002/ijc.26156. PMID 21544803. S2CID 205943879.
Ouriel K, Gray B, Clair DG, Olin J (March 2000). "Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis". Journal of Vascular and Interventional Radiology. 11 (3): 295–298. doi:10.1016/S1051-0443(07)61420-1. PMID 10735422.
Cinà CS, Goh RH, Chan J, Kenny B, Evans G, Rawlinson J, Gill G (November 1999). "Intraarterial catheter-directed thrombolysis: urokinase versus tissue plasminogen activator". Annals of Vascular Surgery. 13 (6): 571–575. doi:10.1007/s100169900300. PMID 10541608. S2CID 470599.
Macfarlane RG, Pilling J (June 1947). "Fibrinolytic activity of normal urine". Nature. 159 (4049): 779. Bibcode:1947Natur.159Q.779M. doi:10.1038/159779a0. PMID 20241608. S2CID 4125748.
Celander DR, Guest MM (August 1960). "The biochemistry and physiology of urokinase". The American Journal of Cardiology. 6 (2): 409–419. doi:10.1016/0002-9149(60)90333-7. PMID 13808740.

ncbi.nlm.nih.gov

"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
"Entrez Gene: PLAU plasminogen activator, urokinase".
Bager R, Kristensen TK, Jensen JK, Szczur A, Christensen A, Andersen LM, et al. (August 2012). "Urokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains". The Journal of Biological Chemistry. 287 (33): 27526–27536. doi:10.1074/jbc.M112.369207. PMC 3431643. PMID 22733817.
Mahmood N, Mihalcioiu C, Rabbani SA (2018). "Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications". Frontiers in Oncology. 8: 24. doi:10.3389/fonc.2018.00024. PMC 5816037. PMID 29484286.

semanticscholar.org

api.semanticscholar.org

Matthews H, Ranson M, Kelso MJ (November 2011). "Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty?". International Journal of Cancer. 129 (9): 2051–2061. doi:10.1002/ijc.26156. PMID 21544803. S2CID 205943879.
Cinà CS, Goh RH, Chan J, Kenny B, Evans G, Rawlinson J, Gill G (November 1999). "Intraarterial catheter-directed thrombolysis: urokinase versus tissue plasminogen activator". Annals of Vascular Surgery. 13 (6): 571–575. doi:10.1007/s100169900300. PMID 10541608. S2CID 470599.
Macfarlane RG, Pilling J (June 1947). "Fibrinolytic activity of normal urine". Nature. 159 (4049): 779. Bibcode:1947Natur.159Q.779M. doi:10.1038/159779a0. PMID 20241608. S2CID 4125748.